JP2009544734A5 - - Google Patents

Download PDF

Info

Publication number
JP2009544734A5
JP2009544734A5 JP2009521989A JP2009521989A JP2009544734A5 JP 2009544734 A5 JP2009544734 A5 JP 2009544734A5 JP 2009521989 A JP2009521989 A JP 2009521989A JP 2009521989 A JP2009521989 A JP 2009521989A JP 2009544734 A5 JP2009544734 A5 JP 2009544734A5
Authority
JP
Japan
Prior art keywords
composition
antagonist
alkyl
substituted
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009521989A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544734A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/074351 external-priority patent/WO2008014338A2/en
Publication of JP2009544734A publication Critical patent/JP2009544734A/ja
Publication of JP2009544734A5 publication Critical patent/JP2009544734A5/ja
Pending legal-status Critical Current

Links

JP2009521989A 2006-07-25 2007-07-25 目の障害の予防および処置のための内皮分化遺伝子ファミリー３（ｅｄｇ−３、ｓ１ｐ３）レセプターのアンタゴニスト Pending JP2009544734A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83308006P 2006-07-25 2006-07-25
PCT/US2007/074351 WO2008014338A2 (en) 2006-07-25 2007-07-25 Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disorders

Publications (2)

Publication Number Publication Date
JP2009544734A JP2009544734A (ja) 2009-12-17
JP2009544734A5 true JP2009544734A5 (cg-RX-API-DMAC7.html) 2011-03-10

Family

ID=38982306

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009521989A Pending JP2009544734A (ja) 2006-07-25 2007-07-25 目の障害の予防および処置のための内皮分化遺伝子ファミリー３（ｅｄｇ−３、ｓ１ｐ３）レセプターのアンタゴニスト

Country Status (11)

Country Link
US (2) US20080025973A1 (cg-RX-API-DMAC7.html)
EP (1) EP2068856A2 (cg-RX-API-DMAC7.html)
JP (1) JP2009544734A (cg-RX-API-DMAC7.html)
KR (1) KR20090033886A (cg-RX-API-DMAC7.html)
CN (1) CN101505744A (cg-RX-API-DMAC7.html)
AU (1) AU2007279311A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0714593A2 (cg-RX-API-DMAC7.html)
CA (1) CA2657480A1 (cg-RX-API-DMAC7.html)
MX (1) MX2009000907A (cg-RX-API-DMAC7.html)
WO (1) WO2008014338A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200900316B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101905023B (zh) * 2004-07-16 2012-07-11 杏林制药株式会社 有效的医药使用方法及与副作用发生的防御相关的方法
PL1806338T3 (pl) 2004-10-12 2016-07-29 Kyorin Seiyaku Kk Sposób wytwarzania chlorowodorku 2-amino-2-[2-[4-(3-benzyloksyfenylotio)-2-chlorofenyio]etylo]-1,3-propanodioiu i jego hydratów oraz produkty pośrednie w ich wytwarzaniu
WO2007043433A1 (ja) * 2005-10-07 2007-04-19 Kyorin Pharmaceutical Co., Ltd. ２－アミノ－１，３－プロパンジオール誘導体を有効成分とする肝臓疾患治療剤および肝臓疾患治療方法
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
KR20090041424A (ko) * 2006-08-08 2009-04-28 교린 세이야꾸 가부시키 가이샤 아미노알코올 유도체 및 그것들을 유효성분으로 하는 면역 억제제
KR101339976B1 (ko) * 2006-08-08 2013-12-10 교린 세이야꾸 가부시키 가이샤 아미노인산에스테르 유도체 및 그들을 유효성분으로 하는 ｓ1ｐ 수용체 조절제
JP5452237B2 (ja) 2008-02-07 2014-03-26 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
WO2009117335A2 (en) * 2008-03-17 2009-09-24 Allergan, Inc. S1p3 receptor inhibitors for treating inflammation
EP2427189A1 (en) * 2009-05-05 2012-03-14 Allergan, Inc. S1p3 receptor inhibitors for treating conditions of the eye
CA2770894A1 (en) * 2009-08-11 2011-02-17 Allergan, Inc. Isothiozoles for treating conditions of the eye
MX2012003844A (es) * 2009-09-30 2012-05-08 Stiefel Res Australia Pty Ltd Espuma cosmetica.
CN102146411B (zh) * 2011-01-06 2013-01-02 中国人民解放军第三军医大学第三附属医院 新型双功能抗瘢痕和组织纤维化寡聚核苷酸药物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013811A1 (de) * 1993-11-17 1995-05-26 Byk Nederland Bv Verwendung substituierter thiazolidinderivate zur behandlung von erhöhtem augeninnendruck
US5545626A (en) * 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
US5750652A (en) * 1994-01-21 1998-05-12 Yale University Deltex proteins
CA2397200C (en) * 2000-02-09 2010-11-23 Connetics Corporation Use of relaxin to treat diseases related to vasoconstriction
JP2001261575A (ja) * 2000-03-13 2001-09-26 General Hospital Corp 血管収縮を調節する方法とその組成物
JP2002332278A (ja) * 2001-05-08 2002-11-22 Human Science Shinko Zaidan Ｅｄｇ受容体拮抗作用を有する複素環誘導体
EP2221054A1 (en) * 2002-04-30 2010-08-25 Alcon, Inc. CDK inhibitors for lowering intraocular pressure
CA2533587A1 (en) * 2002-07-30 2004-02-05 University Of Virginia Patent Foundation Compounds active in sphingosine 1-phosphate signaling
WO2004019938A1 (en) * 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
FR2845003A1 (fr) * 2002-09-30 2004-04-02 Merck Sante Sas Utilisation de derives de thiazolidinedione comme inhibiteurs de l'aldose reductase
EP1646611A1 (en) * 2003-07-15 2006-04-19 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
JP2005247691A (ja) * 2004-03-01 2005-09-15 Toa Eiyo Ltd Ｓ１ｐ３受容体拮抗薬
MX2007006706A (es) * 2004-12-06 2007-10-18 Univ Virginia Analogos de esfingosina 1-fosfato amida de arilo.
US8546452B2 (en) * 2005-10-12 2013-10-01 Toa Eiyo Ltd. S1P3 receptor antagonist
CN101460458A (zh) * 2006-02-15 2009-06-17 阿勒根公司 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物

Similar Documents

Publication Publication Date Title
JP2009544734A5 (cg-RX-API-DMAC7.html)
AU2025271125A1 (en) Methods for treating or preventing ophthalmological conditions
JP2017514917A5 (cg-RX-API-DMAC7.html)
US20080025973A1 (en) Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disorders
DE60307607D1 (de) Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
IL308752B2 (en) RNAi factors, compositions and methods of using them for treating transthyretin-related diseases
WO2010125416A1 (en) Drug delivery to the anterior and posterior segments of the eye
JP2011518116A (ja) トール様受容体３拮抗薬としての超小型ｒｎａ
JP2023099171A (ja) 緑内障を治療するためのＷｎｔ５ａの調節
JP2017524012A (ja) 眼科症状を処置するまたは予防するための方法
KR20150013867A (ko) 제브라피시 모델을 사용한 약물 스크리닝 방법 및 이 방법으로 스크린된 화합물
JP2006516957A (ja) Ｉｌ−６アンタゴニストの抗血管形成用途
EP3747471A1 (en) Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
JP2020505365A (ja) 治療用および神経保護用ペプチド
JP7474706B2 (ja) ４－フェニル酪酸を含有する老視の治療または予防剤
WO2014138018A1 (en) Preservative free bimatoprost and timolol solutions
JP2013535495A (ja) 病的血管新生に関連する病気を予防し、安定させかつ／または阻害するための注射可能な医薬組成物
O'Brien et al. Metastatic Staphylococcus aureus endophthalmitis: a case report.
JP2014521648A (ja) 網膜疾患を治療するための４−ブロモ−ｎ−（イミダゾリジン−２−イリデン）−１ｈ−ベンゾイミダゾール−５−アミンを含む医薬組成物
EP4574146A1 (en) Dhp-i inhibitors for use as neuroprotectants and in the treatment of neuroinflammatory diseases
Tachibana et al. Reduced vitreal concentration of periostin after vitrectomy in patients with proliferative diabetic retinopathy.
RU2023125207A (ru) СРЕДСТВА ДЛЯ РНКи, КОМПОЗИЦИИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, АССОЦИИРОВАННЫХ С ТРАНСТИРЕТИНОМ (TTR)
JPWO2020180865A5 (cg-RX-API-DMAC7.html)
JPWO2022232586A5 (cg-RX-API-DMAC7.html)
JP2005533082A5 (cg-RX-API-DMAC7.html)